Advertisement

Reactions Weekly

, Volume 1695, Issue 1, pp 78–78 | Cite as

Bortezomib/rituximab

Thrombocytopenia and anaemia aggravation: 2 case reports
Case report
  • 29 Downloads

Reference

  1. Zilioli VR, et al. Rituximab plus bortezomib still represents an effective treatment option for patients with relapsed or refractory mantle cell lymphoma. Blood 130 (Suppl. 1): no pagination, Dec 2017 [abstract] - ItalyGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations